Sign Up to like & get
recommendations!
0
Published in 2020 at "Oncoimmunology"
DOI: 10.1080/2162402x.2020.1845424
Abstract: ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is one of the most common tumor subtypes and remains associated with very poor survival. T cell infiltration into tumor tissue is associated with improved clinical outcome but little is…
read more here.
Keywords:
phenotype;
tumor tissue;
tumor;
cells pancreatic ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "BMC Cancer"
DOI: 10.1186/s12885-019-5744-8
Abstract: BackgroundWith the increase in cancer survivors, more pancreatic ductal adenocarcinomas (PDACs) are developing as second primary cancers. Whether a prior cancer has an inferior impact on survival outcomes in patients with PDAC remains unknown, and…
read more here.
Keywords:
outcomes patients;
survival outcomes;
analysis;
patients pdac ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246223
Abstract: Simple Summary Metastatic pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that has limited treatment options. Standard of care treatment involves systemic chemotherapy, although all tumors invariably develop resistance to these cytotoxic therapies. With the…
read more here.
Keywords:
metastatic pancreatic;
targeted therapies;
patients pdac;
adenocarcinoma ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Cancers"
DOI: 10.3390/cancers15030897
Abstract: Simple Summary During the last decades, the CA 19-9 blood test has been the only widely used biomarker in patients with pancreatic ductal adenocarcinoma (PDAC). Given the poor prognosis and staggering mortality rates of this…
read more here.
Keywords:
ductal adenocarcinoma;
value;
patients pdac;
pancreatic ductal ... See more keywords